You are here: Industry Insights > mRNA

News List

Arcturus Therapeutics, Catalent announce partnership to manufacture mRNA-based Covid-19 pharmaceutical-business-review
May 08, 2020
Arcturus Therapeutics Holdings, a leading clinical-stage messenger RNA (mRNA) medicines and vaccines company, and Catalent announced a partnership to support the expected manufacture of Arcturus’ COVID-19 mRNA vaccine candidate (LUNAR-COV19) .
First Patient Dosed With Pfizer’s Potential COVID-19 Vaccine in US europeanpharmaceuticalreview
May 07, 2020
Pfizer and BioNTech have initiated Phase I/II trials in the US to determine the safety and optimal dose of four mRNA COVID-19 vaccine candidates.
Ethris, Neurimmune work on inhalable COVID-19 therapy pharmatimes
April 02, 2020
Joining the fight against COVID-19, Ethris GmbH and Neurimmune AG have announced an exclusive partnership to develop an mRNA-based anti-SARS-CoV-2 antibody therapeutic as an inhalable COVID-19 treatment.
Moderna Leads Coronavirus Vaccine Charge contractpharma
March 19, 2020
First participant dosed in NIH-led Phase 1 study of mRNA vaccine against novel coronavirus.
CureVac works on mRNA vaccine for coronavirus pharmaceutical-technology
March 17, 2020
German biopharmaceutical company CureVac is working on the development of an mRNA-based vaccine to protect against Covid-19 coronavirus infection.
Genmab, CureVac Enter Partnership to Develop mRNA-based Antibody Therapeutics americanpharmaceuticalreview
December 23, 2019
Genmab and CureVac have entered into a research collaboration and license agreement. This strategic partnership will focus on the research and development of ...
CureVac, Yale Collaborate on Discovery Research contractpharma
August 14, 2019
Will focus on developing novel mRNA-based candidates for pulmonary diseases.
Sanofi invests €80M in BioNTech as cancer mRNA hits clinic fiercebiotech
January 07, 2019
Sanofi is set to invest €80 million ($91 million) in BioNTech and extend its cancer collaboration with the German mRNA specialist. The agreement comes as BioNTech and Sanofi prepare to .....
Moderna’s cash juggernaut rolls on with record $604M IPO fiercebiotech
December 28, 2018
Moderna’s IPO always looked like a record breaker for biotech and came in even larger than expected at $604 million, valuing the company at an eye-watering $7.9 billion.....
BioNTech Signs Collaboration Agreement with Pfizer to Develop mRNA-based Vaccines for Prevention of Influenza pharmafocusasia
November 27, 2018
BioNTech AG, a rapidly growing biotechnology company focused on precise immunotherapies for the treatment of cancer and infectious disease...